Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP879619.RAseJzIxAGXuvSX1ilCPLVUfajcwEeVgOib-WXhuwMf2I130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP879619.RAseJzIxAGXuvSX1ilCPLVUfajcwEeVgOib-WXhuwMf2I130_assertion type Assertion NP879619.RAseJzIxAGXuvSX1ilCPLVUfajcwEeVgOib-WXhuwMf2I130_head.
- NP879619.RAseJzIxAGXuvSX1ilCPLVUfajcwEeVgOib-WXhuwMf2I130_assertion wasGeneratedBy ECO_0000203 NP879619.RAseJzIxAGXuvSX1ilCPLVUfajcwEeVgOib-WXhuwMf2I130_provenance.
- NP879619.RAseJzIxAGXuvSX1ilCPLVUfajcwEeVgOib-WXhuwMf2I130_assertion wasDerivedFrom befree-2016 NP879619.RAseJzIxAGXuvSX1ilCPLVUfajcwEeVgOib-WXhuwMf2I130_provenance.
- NP879619.RAseJzIxAGXuvSX1ilCPLVUfajcwEeVgOib-WXhuwMf2I130_assertion SIO_000772 21406037 NP879619.RAseJzIxAGXuvSX1ilCPLVUfajcwEeVgOib-WXhuwMf2I130_provenance.
- NP879619.RAseJzIxAGXuvSX1ilCPLVUfajcwEeVgOib-WXhuwMf2I130_assertion evidence source_evidence_literature NP879619.RAseJzIxAGXuvSX1ilCPLVUfajcwEeVgOib-WXhuwMf2I130_provenance.
- NP879619.RAseJzIxAGXuvSX1ilCPLVUfajcwEeVgOib-WXhuwMf2I130_assertion description "[The amplification of certain RTKs (ErbB2, c-Met and FGFR2) is associated with gastric cancer progression, but the only recently approved inhibitor is trastuzumab, ErbB2-targeting antibody.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP879619.RAseJzIxAGXuvSX1ilCPLVUfajcwEeVgOib-WXhuwMf2I130_provenance.